Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 9/20 | 0.54 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | LDLR | P01130 | 2/20 | 0.49 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23381359 | 0.95 | KLKB1 (0.57) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL22753492 | 0.93 | KLKB1 (0.59) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL23381035 | 0.92 | KLKB1 (0.67) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL23380898 | 0.90 | KLKB1 (0.55) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL23380995 | 0.89 | KLKB1 (0.58) | KLKB1EPHA2ACEACE2 | |
| SCHEMBL23381228 | 0.89 | EPHA2 (0.58) | KLKB1EPHA2ACEACE2KLK5 | |
| SCHEMBL23381119 | 0.88 | KLKB1 (0.67) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL23380915 | 0.87 | KLKB1 (0.66) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL22753507 | 0.86 | KLKB1 (0.58) | KLKB1EPHA2CTSGACEACE2 | |
| SCHEMBL23380874 | 0.86 | KLKB1 (0.59) | KLKB1EPHA2ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | KLKB1 322/4885EPHA2 364/4885CTSG 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.